RIPK1 and ovarian neoplasm: First, A20 can remove K63‐linked ubiquitin chains from RIPK1, which depends on its deubiquitinating (DUB) activity of the amino‐terminal ovarian tumor (OTU) domain, and add K48‐linked ubiquitin to RIPK1, which is dependent on its Ub‐binding function of zinc finger (ZnF) domains, thus targeting RIPK1 for proteasomal degradation, ultimately preventing the activation of NF‐κB and protecting the cells [70, 71].